human
metapneumoviru
hmpv
respiratori
viru
detect
allogen
hematopoiet
stem
cell
transplant
hsct
recipi
caus
signific
morbid
mortal
given
lack
effect
antivir
investig
potenti
immunotherapeut
intervent
use
adopt
transfer
cell
thu
character
cellular
immun
respons
viru
identifi
f
n
p
immunodomin
target
antigen
reactiv
cell
polyclon
ie
express
thelper
type
polar
polyfunct
ie
produc
interferon
tumor
necrosi
factor
granulocytemacrophag
colonystimul
factor
granzym
b
abl
kill
autolog
antigenload
target
detect
hmpvspecif
cell
hsct
recipi
endogen
control
activ
infect
support
clinic
import
tcell
immun
mediat
protect
antivir
effect
result
demonstr
feasibl
develop
immunotherapi
immunocompromis
patient
uncontrol
infect
adopt
transfer
virusspecif
cell
vst
proven
safe
effect
mean
prevent
treat
infect
associ
rang
latent
virus
caus
morbid
mortal
allogen
hematopoiet
stem
cell
transplant
hsct
recipi
includ
cytomegaloviru
epsteinbarr
viru
bk
viru
human
herpesviru
adenoviru
also
proven
suscept
approach
howev
increasingli
appar
infect
season
virus
human
metapneumoviru
hmpv
clinic
problemat
result
prolong
hospit
fatal
viru
progress
upper
lower
respiratori
tract
infect
henc
goal
current
studi
explor
potenti
target
hmpv
immunotherapeut
approach
hmpv
negativesens
singlestrand
rna
viru
famili
paramyxovirida
gene
encod
follow
protein
nucleocapsid
protein
n
phosphoprotein
p
matrix
protein
fusion
protein
f
transcript
elong
factor
rna
synthesi
regulatori
factor
small
hydrophob
surfac
protein
sh
major
attach
glycoprotein
g
larg
polymeras
subunit
l
figur
glycoprotein
f
sh
g
essenti
target
cell
entri
n
p
l
respons
viral
replic
gene
transcript
transcript
addit
regul
base
phylogenet
analys
hmpv
subdivid
major
lineag
b
subcategor
equal
preval
hmpv
ubiquit
viru
virtual
popul
expos
age
year
infect
frequent
detect
winter
associ
symptom
includ
rhinorrhea
fever
cough
wheez
although
viral
infect
individu
compet
immun
system
usual
well
control
hmpv
infect
immunocompromis
allogen
hsct
recipi
incid
respons
sever
symptom
includ
pneumonia
bronchiol
develop
lower
respiratori
tract
infect
proven
fatal
case
current
approv
prevent
vaccin
antivir
drug
although
nucleosid
analog
ribavirin
without
intraven
immunoglobulin
use
therapeut
result
inconsist
consider
associ
toxic
eg
hemolyt
anemia
cytopenia
hmpv
might
suitabl
candid
target
adopt
immunotherapi
treatment
develop
evid
cell
recogn
viru
present
peripher
blood
healthi
virusexpos
individu
cell
mediat
antivir
effect
upon
encount
infect
cell
demonstr
hmpvreactiv
cell
inde
exist
peripher
blood
healthi
subject
hsct
recipi
respiratori
tract
infect
base
number
respond
donor
magnitud
reactiv
cell
establish
hierarchi
antigen
immunodomin
furthermor
show
cell
reactiv
immunogen
antigen
readili
expand
ex
vivo
exhibit
polyclon
thelper
type
polar
profil
kill
antigenexpress
target
thu
anticip
expand
tcell
popul
prove
clinic
valuabl
prevent
treat
hmpv
infect
immunocompromis
individu
peripher
blood
mononuclear
cell
pbmc
obtain
healthi
donor
allogen
hsct
recipi
inform
consent
baylor
colleg
medicin
institut
review
boardapprov
protocol
use
gener
hmpvdirect
virusspecif
cell
vst
phytohemagglutinin
pha
blast
pha
blast
gener
pbmc
cellsml
plate
use
pha
pbmc
stimul
use
pepmix
peptid
librari
overlap
amino
acid
span
antigen
n
p
f
sh
g
l
deriv
hmpv
strain
hmpv
substrain
pepmix
synthes
jpt
peptid
technolog
berlin
germani
lyophil
pepmix
reconstitut
dimethyl
sulfoxid
sigmaaldrich
st
loui
mo
store
fifteen
million
freshfrozen
pbmc
pellet
tube
puls
minut
pepmix
concentr
pbmc
resuspend
vst
medium
supplement
uml
interleukin
ngml
interleukin
r
system
minneapoli
mn
plate
either
plate
cellswel
transfer
devic
devis
wilson
wolf
minneapoli
mn
medium
cytokin
replenish
day
cultur
split
reach
densiti
cellswel
plate
cell
devic
day
vst
harvest
count
use
phenotyp
function
studi
second
stimul
hmpvspecif
cell
plate
irradi
gy
pepmixpuls
autolog
pha
blast
cell
resuspend
ml
vst
medium
supplement
interleukin
interleukin
transfer
devic
day
day
cultur
replenish
fresh
medium
supplement
ngml
interleukin
cellgenix
freiburg
germani
day
vst
harvest
use
studi
immunophenotyp
hmpvspecif
cell
surfac
stain
monoclon
antibodi
becton
data
analyz
use
kaluza
flow
cytometri
analysi
softwar
beckman
coulter
vst
harvest
resuspend
concentr
cellsml
vst
medium
plate
plate
cell
stimul
ng
test
control
pepmix
presenc
brefeldin
monensin
bd
overnight
subsequ
vst
wash
pb
pellet
surfac
stain
incub
minut
dark
wash
pellet
fix
permeabil
cytofixcytoperm
solut
bd
minut
dark
wash
pb
contain
fetal
bovin
serum
saponin
bd
cell
incub
interferon
tumor
necrosi
factor
antibodi
bd
minut
dark
cell
wash
twice
cold
pb
contain
fetal
bovin
serum
saponin
least
live
cell
popul
analyz
facscalibur
equip
gallio
softwar
data
analyz
use
kaluza
flow
cytometri
analysi
softwar
beckman
coulter
stain
perform
use
ebiosci
kit
per
manufactur
instruct
briefli
vst
rest
medium
without
cytokin
hour
cell
wash
pb
surfac
stain
antibodi
bd
minut
cell
wash
resuspend
ml
fixationpermeabil
buffer
incub
hour
dark
wash
pb
cell
resuspend
permeabil
buffer
incub
isotyp
antibodi
clone
minut
follow
final
wash
cell
acquir
analyz
facscalibur
data
analyz
use
kaluza
flow
cytometri
analysi
softwar
beckman
coulter
elispot
analysi
use
quantit
frequenc
antigenspecif
granzym
bproduc
cell
pbmc
hmpvspecif
cell
resuspend
cellsml
respect
vst
medium
cell
ad
elispot
well
antigenspecif
activ
measur
direct
stimul
ngpeptideml
individu
hmpv
pepmix
n
p
f
measur
cytotox
specif
hmpvspecif
cell
standard
cr
releas
assay
use
effector
target
ratio
vst
use
effector
target
autolog
pha
blast
puls
pepmix
autolog
pha
blast
alon
use
specif
control
sinc
littl
known
tcell
respons
hmpv
isol
pbmc
healthi
donor
stimul
pepmix
span
viral
antigen
evalu
frequenc
antigenspecif
cell
circul
peripher
blood
use
elispot
assay
shown
figur
magnitud
activ
peripher
blood
low
exampl
figur
determin
whether
appar
pauciti
hmpvreactiv
cell
peripher
blood
simpli
reflect
frequenc
cell
limit
detect
elispot
assay
perform
singl
vitro
stimul
assay
select
amplifi
specif
cell
thu
expos
pbmc
healthi
individu
age
rang
year
mean
age
year
mastermix
hmpv
peptid
librari
allow
reactiv
cell
expand
day
overal
achiev
mean
foldincreas
total
cell
number
n
figur
expand
popul
compris
cell
mix
cytotox
cell
helper
cell
figur
evid
regulatori
tcell
outgrowth
assess
stain
supplementari
figur
figur
next
determin
whether
enrich
hmpvreactiv
cell
assess
specif
elispot
assay
shown
figur
readili
abl
expand
popul
specif
antigen
except
fold
enrich
achiev
summar
figur
data
suggest
hmpvspecif
cell
resid
memori
pool
readili
amplifi
ex
vivo
sought
identifi
hierarchi
immunodomin
base
number
donor
posit
respond
antigen
cell
magnitud
respons
base
absolut
number
sfc
per
input
cell
tabl
f
recogn
donor
screen
induc
highest
frequenc
specif
cell
mean
input
cell
follow
descend
order
n
n
respect
n
p
n
l
n
g
n
reactiv
sh
detect
donor
screen
input
cell
wherea
immunogen
notabl
major
donor
screen
recogn
express
antigen
figur
thu
subsequ
function
studi
chose
focu
top
immunogen
target
antigen
f
n
p
evalu
whether
hmpv
specif
mediat
predominantli
andor
tcell
subset
perform
intracellular
cytokin
stain
studi
gate
cell
antigen
specif
determin
product
either
cytokin
detect
predominantli
tcell
compart
minor
compon
figur
show
fluorescenceactiv
cellsort
data
repres
donor
figur
summar
data
donor
studi
product
multipl
proinflammatori
cytokin
effector
molecul
report
correl
enhanc
cytolyt
function
improv
vivo
activ
thu
comprehens
explor
function
profil
expand
vst
found
major
cell
figur
also
produc
detail
result
donor
shown
figur
data
donor
summar
figur
furthermor
line
produc
granulocytemacrophag
colonystimul
factor
gmcsf
figur
well
granzym
b
mean
input
cell
f
n
p
n
donor
screen
figur
product
cytokin
includ
interleukin
interleukin
detect
level
similar
control
vst
figur
thu
expans
hmpvreactiv
cell
induc
polyclon
tcell
line
determin
whether
expand
hmpvspecif
cell
cytolyt
cocultur
hmpvspecif
cell
cr
peptideload
autolog
pha
blast
unload
pha
blast
serv
control
shown
figur
hmpvload
target
specif
recogn
lyse
expand
hmpvspecif
cell
effector
target
ratio
test
mean
percentag
lysi
ratio
n
contrast
control
target
cell
kill
mean
percentag
lysi
ratio
final
assess
clinic
relev
hmpvspecif
cell
investig
whether
allogen
hsct
recipi
evid
amplifi
level
cell
direct
identifi
immunodomin
target
antigen
peripher
blood
andor
clearanc
hmpv
infect
figur
show
result
patient
girl
develop
upper
respiratori
tract
infect
nasal
wash
sampl
sinc
symptom
resolv
day
transplant
receipt
myeloabl
transplant
proceed
schedul
hmpv
remain
detect
rvp
pcr
day
transplant
assess
whether
reconstitut
hmpvspecif
cell
contribut
viral
clearanc
collect
blood
specimen
week
hsct
receipt
measur
specif
tcell
activ
shown
figur
patient
exhibit
strong
tcell
activ
earli
week
transplant
subsequ
declin
coincid
viral
clearanc
abl
detect
similar
pattern
tcell
activ
addit
transplant
recipi
confirm
hmpv
infect
clear
result
summar
supplementari
tabl
supplementari
figur
c
studi
character
tcell
immun
respons
viral
encod
hmpv
antigen
base
frequenc
respond
donor
magnitud
reactiv
cell
abl
defin
hierarchi
immunodomin
f
immunogen
follow
descend
order
n
p
l
g
sh
immunogen
reactiv
cell
could
readili
enrich
vitro
polyclon
polyfunct
produc
gmcsf
granzym
b
abl
kill
autolog
antigenload
target
cell
final
potenti
clinic
benefit
follow
adopt
transfer
cell
infer
detect
reactiv
tcell
popul
peripher
blood
allogen
hsct
recipi
success
clear
activ
hmpv
infect
lack
effect
treatment
hmpv
immunocompromis
patient
led
group
investig
potenti
use
adopt
transfer
donorderiv
cell
prevent
andor
treat
hmpv
infect
given
success
approach
clinic
problemat
virus
includ
cytomegaloviru
epsteinbarr
viru
bk
viru
human
herpesviru
adenoviru
thu
first
sought
identifi
appropri
hmpv
antigen
effector
tcell
respons
might
gener
prior
current
studi
limit
inform
immun
hmpv
although
evid
suggest
import
cellmedi
humor
antivir
activ
exampl
immunocompromis
individu
eg
human
immunodefici
virusinfect
patient
steroidtr
hsct
recipi
hmpv
infect
sever
sometim
fatal
treatment
intraven
immunoglobulin
proven
benefici
murin
studi
kolli
et
al
intranas
infect
balbc
mice
laboratori
strain
hmpv
expos
anim
uvinactiv
hmpv
demonstr
deplet
either
cell
compromis
anim
abil
controlclear
viral
challeng
similarli
hast
et
al
vaccin
transgen
mice
either
hmpv
mderiv
tcell
epitop
irrelev
control
challeng
live
hmpv
strain
demonstr
viral
load
lung
vaccin
anim
significantli
lower
control
mice
final
herd
et
al
demonstr
cell
effector
profil
character
product
prototyp
cytokin
gmcsf
interleukin
proinflammatori
chemokin
macrophag
inflammatori
protein
protein
abl
accumul
lung
follow
hmpv
infect
howev
sinc
immun
studi
human
virus
perform
anim
alway
faith
recapitul
studi
perform
natur
host
sought
analyz
tcell
respons
hmpv
healthi
human
subject
hmpvinfect
hsct
recipi
initi
studi
healthi
adult
discov
frequenc
circul
hmpvreactiv
cell
threshold
detect
assay
elispot
howev
reactiv
cell
could
readili
expand
number
clinic
relev
singl
vitro
stimul
identifi
encod
antigen
induc
protect
immun
took
approach
first
profil
expand
tcell
product
determin
antigen
frequent
recogn
major
donor
screen
healthi
individu
identifi
clear
hierarchi
immunodomin
f
frequent
recogn
follow
n
p
l
g
sh
immunogen
second
examin
peripher
blood
specimen
allogen
hsct
recipi
activ
hmpv
infect
confirm
rvp
pcr
success
clear
hmpv
coincid
amplif
reactiv
cell
subsid
upon
viral
clearanc
final
establish
feasibl
use
adopt
transfer
cell
prophylact
therapeut
approach
immunocompromis
patient
demonstr
hmpvreactiv
cell
effector
profil
success
expand
clinic
relev
number
vitro
mean
manufactur
approach
compliant
good
manufactur
practic
taken
togeth
studi
support
develop
futur
clinic
trial
adopt
transfer
hmpvspecif
cell
specif
either
prophylact
therapeut
use
immunocompromis
patient
supplementari
materi
avail
journal
infecti
diseas
onlin
consist
data
provid
author
benefit
reader
post
materi
copyedit
b
cytolyt
potenti
hmpvspecif
cell
evalu
standard
cr
releas
assay
use
hmpv
pepmixpuls
phytohemagglutinin
blast
target
n
c
peripher
blood
mononuclear
cell
pbmc
isol
hematopoiet
stem
cell
transplant
recipi
patient
acut
hmpv
infect
test
specif
panel
hmpv
antigen
use
interferon
elispot
readout
sem
standard
error
mean
sole
respons
author
question
comment
address
correspond
author
